Abstract: Daraxonrasib (RMC-6236) is a novel, first-in-class, orally bioavailable, pan-RAS(ON) multi-selective tri-complex inhibitor that represents a significant breakthrough in the treatment of RAS-driven malignancies, particularly Non-Small Cell Lung Cancer (NSCLC). Unlike first-generation KRAS G12C inhibitors that target the inactive GDP-bound state, RMC-6236 binds to the active GTP-bound state of multiple RAS isoforms (KRAS, HRAS, NRAS), encompassing both mutant and wild-type forms. By recruiting cyclophilin A (CypA) to form a sterically inhibitory tri-complex, it effectively blocks downstream oncogenic signaling pathways. Preclinical and early clinical data demonstrate robust antitumor activity, including a high objective response rate and disease control rate in NSCLC. Furthermore, its ability to cross the blood-brain barrier positions it as a highly promising therapeutic option for NSCLC patients with brain metastases. This review synthesizes current literature on the pharmacological activity, molecular mechanisms, structure-activity relationships, limitations, and future clinical perspectives of Daraxonrasib in NSCLC.
1. Introduction
Non-small cell lung cancer (NSCLC) accounts for the vast majority of lung cancer cases and is frequently driven by mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS). Historically, KRAS was considered an "undruggable" target. The development of first-generation covalent inhibitors, such as sotorasib and adagrasib, marked a major milestone by successfully targeting the KRAS G12C mutation in its inactive GDP-bound state (RAS-OFF) [2] [3]. However, these therapies are limited by their narrow applicability (only targeting the G12C mutation) and the rapid emergence of adaptive resistance [3].
To address these therapeutic gaps, broad-spectrum pan-RAS inhibitors have been developed. Daraxonrasib, also known as RMC-6236, is a pioneering nonsteroidal, noncovalent multi-selective inhibitor designed to target the active, GTP-bound form of RAS (RAS-ON) [1]. By targeting multiple RAS isoforms (KRAS, HRAS, and NRAS) and various mutations (including G12X variants), RMC-6236 offers a broader coverage of KRAS-mutant tumors, providing new hope for patients with advanced NSCLC, including those with challenging clinical presentations such as brain metastases [2] [3].
2. Pharmacological Activity
Daraxonrasib exhibits potent pharmacological activity in both preclinical models and early-phase clinical trials. In preclinical xenograft models, RMC-6236 demonstrated a favorable distribution profile, with concentrations in tumor tissue reaching 3 to 7 times higher than in the blood, alongside a slower clearance rate from tumors compared to other tissues [2]. The compound induces durable antitumor activity and frequent tumor regression across multiple KRAS G12X NSCLC mouse models [2].
Crucially for NSCLC, RMC-6236 is highly permeable to the blood-brain barrier (BBB). It has demonstrated significant treatment responses in KRAS G12C mutant mouse brain tumor xenograft models, expanding the therapeutic landscape for NSCLC patients who frequently develop brain metastases [2] [3].
In the clinical setting, interim data from the Phase I trial (NCT05379985) evaluating RMC-6236 in patients with advanced solid tumors revealed highly promising efficacy in NSCLC. The drug achieved an Objective Response Rate (ORR) of approximately 38% and a Disease Control Rate (DCR) of 85% in NSCLC patients [3]. Furthermore, RMC-6236 exhibits immunomodulatory effects on the tumor microenvironment (TME). It enhances the infiltration of CD4+ and CD8+ T cells, increases the expression of major histocompatibility complex class II (MHC II) molecules on tumor cells, reduces tumor vascularity, and decreases the presence of immunosuppressive cells such as M2-like macrophages and myeloid-derived suppressor cells (MDSCs) [3].
3. Molecular Mechanism of Action
Unlike allele-specific covalent inhibitors that lock KRAS in an inactive GDP-bound state, Daraxonrasib functions as a RAS(ON) inhibitor. It specifically binds to the active, GTP-bound state of all RAS isoforms (KRAS, HRAS, and NRAS), encompassing both mutant and wild-type forms [3].
Mechanistically, RMC-6236 acts as a molecular glue. It recruits and binds to the intracellular chaperone protein cyclophilin A (CypA). This binary complex then binds to the active RAS-GTP protein, forming a noncovalent, sterically inhibitory tri-complex (RMC-6236–CypA–RAS-GTP) [1] [2]. By locking RAS in this conformationally restricted state, the tri-complex sterically blocks RAS from engaging with its downstream effector proteins, such as RAF kinases, PI3K (phosphoinositide 3-kinase), and RAL-GDS (RAL guanine nucleotide dissociation stimulator). Consequently, this neutralizes the oncogenic signal and effectively silences downstream MAPK and PI3K/AKT signaling pathways [3].
4. Structure-Activity Relationship (SAR)
The structural design of Daraxonrasib allows it to exploit the cellular machinery to achieve high affinity and broad-spectrum inhibition. The inhibitor occupies the switch II pocket (SII-P) of the RAS protein while simultaneously remodeling the surface of CypA to create a high-affinity binding interface for the GTP-bound state of RAS variants [2] [3].
Quantitative binding studies highlight the compound's potent affinities. RMC-6236 associates with CypA with a high affinity (kd = 55.3 nmol/L). The resulting RMC-6236–CypA complex subsequently binds to various RAS-GTP targets with distinct affinities: KRAS G12D (kd = 131 nmol/L), KRAS G12V (kd = 364 nmol/L), and wild-type KRAS (kd = 154 nmol/L) [2]. This structural mechanism reduces the dynamic flexibility of RAS-GTP necessary for effector binding, allowing the drug to neutralize RAS signaling at its active state across multiple isoforms [3].
5. Current Limitations
Despite its promising profile, the clinical application of Daraxonrasib faces several limitations and challenges:
Toxicity and Safety: Because RMC-6236 targets wild-type RAS in addition to mutant forms, there are concerns regarding the disruption of normal tissue homeostasis. In early clinical trials, the most common treatment-related adverse events included rash, diarrhea, nausea, vomiting, stomatitis, fatigue, paronychia, mucosal inflammation, and peripheral edema [1]. While mostly Grade 1 or 2, Grade 3 events do occur, and approximately 5% of patients discontinued treatment due to adverse effects [3].
Adaptive Resistance: While pan-RAS inhibitors restrict the diversity of potential escape mutations compared to mutation-specific inhibitors, resistance can still emerge. When RAS signaling is broadly inhibited, cancer cells can activate compensatory bypass mechanisms, notably the YAP (Yes-associated protein) and TAZ transcriptional coactivators. The activation of the YAP/TAZ–TEAD complex promotes cell survival and proliferation by suppressing proapoptotic genes and maintaining downstream PI3K/AKT/mTOR signaling, allowing tumors to escape RAS dependency [3].
6. Future Perspectives
The future clinical development of Daraxonrasib in NSCLC is focused on optimizing its efficacy, overcoming resistance, and validating its role in advanced disease settings.
Advanced Clinical Trials: RMC-6236 is currently advancing through the clinical pipeline. A global Phase 3 clinical trial (RASolve 301 / NCT06881784) is actively recruiting to evaluate the efficacy of RMC-6236 compared to docetaxel chemotherapy in patients with advanced RAS-mutant NSCLC, including those with stable brain metastases [2].
Combination Therapies: To counteract adaptive resistance mechanisms, combination strategies are being heavily investigated. Combining RMC-6236 with YAP-TEAD interaction inhibitors (e.g., IAG933) shows potential in preclinical models to suppress MYC expression and bypass resistance [3]. Furthermore, because RMC-6236 remodels the immunosuppressive TME, combining it with immune checkpoint inhibitors (such as anti-PD-1 therapies) may yield synergistic antitumor effects by negating immune evasion [3]. Other trials (e.g., NCT06162221) are exploring combinations of RMC-6236 with standard of care or other novel RAS inhibitors like RMC-6291 and RMC-9805 [1].
Biomarker Development: The identification of predictive biomarkers, such as MHC-II expression or specific T-cell clonality, will be critical for selecting NSCLC patients most likely to benefit from pan-RAS inhibitors and for monitoring therapeutic responses [3].
